UK-based AstraZeneca's Lokelma (sodium zirconium
cyclosilicate) has achieved statistically significant and clinically meaningful improvement in treating hyperkalaemia in patients with end-stage renal disease on haemodialysis in the phase 111b Dialize trial, it was reported on Monday.
Bands corresponding to the vibrations coming from
cyclosilicate units (at about 620 [cm.sup.-1]) were also observed [30-37].
Lokelma (sodium zirconium
cyclosilicate) is a nonabsorbed zirconium silicate that exchanges potassium for hydrogen and sodium.
Newer agents for treating hyperkalemia include sodium zirconium
cyclosilicate and patiromer.
Moreover, the FDA recently approved Lokelma (sodium zirconium
cyclosilicate), formerly ZS-9, for the treatment of hyperkalemia, a serious condition characterized by high potassium levels in the blood associated with cardiovascular, renal and metabolic diseases.
Tourmaline, with the chemical formula of Na[R.sub.3][Al.sub.6](-[Si.sub.6][O.sub.18]) [(B[O.sub.3]).sub.3] [(OH,F).sub.4] (R is Mg, Fe, Li, or Mn) [3-5], is a natural
cyclosilicate mineral.
Newer agents, including sodium zirconium
cyclosilicate and patiromer have been studied for the use management of chronic hyperkalemia in patients with CKD [3, 11, 12].
Beryl, [Be.sub.3][Al.sub.2][Si.sub.6][O.sub.18], is a common, rock-forming
cyclosilicate mineral, generally occuring within granites and granitic pegmatites.
In his commentary on the poem, Italo Calvino points out that emerald is a kind of beryl (a
cyclosilicate containing beryllium) and concludes that the whole line is based on approximate homophony, identifying the lude as: "Au beryl d'emeraude un glucinium" (Calvino 163-164).
United Kingdom-based AstraZeneca has received approval from The US Food and Drug Administration (FDA) for its Lokelma (sodium zirconium
cyclosilicate), formerly ZS-9, intended for the treatment of hyperkalaemia in adults, it was reported yesterday.